These findings suggest that the simultaneous detection of serum‐derived exosomal PIK3CAH1047R mutation and serum IL6 secretion may serve as a promising diagnostic and prognostic tool for CRC and simultaneous targeting of PIK3CAH1047R mutation and IL6 may serve as a novel approach for the treatment of CRC. The gene discussed is IL6; the disease is colorectal carcinoma.